Naïm Bouazza

Summary

Country: France

Publications

  1. ncbi Population pharmacokinetics of clindamycin orally and intravenously administered in patients with osteomyelitis
    Naïm Bouazza
    EA 3620, Universite Paris Descartes, Sorbonne Paris Cité, Paris, France
    Br J Clin Pharmacol 74:971-7. 2012
  2. ncbi Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children?
    Naïm Bouazza
    EA 3620, Universite Paris Descartes, Unite de recherche clinique, Hôpital Tarnier, 89 rue d Assas, 75006 Paris, France
    Antimicrob Agents Chemother 54:3280-6. 2010
  3. ncbi Developmental pharmacokinetics of lamivudine in 580 pediatric patients ranging from neonates to adolescents
    Naïm Bouazza
    EA 3620, Universite Paris Descartes, Paris, France
    Antimicrob Agents Chemother 55:3498-504. 2011
  4. ncbi Population pharmacokinetics of tenofovir in HIV-1-infected pediatric patients
    Naïm Bouazza
    EA 3620, Universite Paris Descartes, Sorbonne Paris Cité France, Paris, France
    J Acquir Immune Defic Syndr 58:283-8. 2011
  5. ncbi Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients
    Naïm Bouazza
    EA 3620, Universite Paris Descartes, Sorbonne Paris Cité, France
    Orphanet J Rare Dis 6:86. 2011
  6. ncbi Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women
    Sihem Benaboud
    Université Paris Descartes Sorbonne Paris Cité, EA3620, Paris, France
    Antimicrob Agents Chemother 56:857-62. 2012
  7. ncbi Pregnancy-related effects on lamivudine pharmacokinetics in a population study with 228 women
    Sihem Benaboud
    Universite Paris Descartes, Paris, France
    Antimicrob Agents Chemother 56:776-82. 2012

Detail Information

Publications7

  1. ncbi Population pharmacokinetics of clindamycin orally and intravenously administered in patients with osteomyelitis
    Naïm Bouazza
    EA 3620, Universite Paris Descartes, Sorbonne Paris Cité, Paris, France
    Br J Clin Pharmacol 74:971-7. 2012
    ....
  2. ncbi Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children?
    Naïm Bouazza
    EA 3620, Universite Paris Descartes, Unite de recherche clinique, Hôpital Tarnier, 89 rue d Assas, 75006 Paris, France
    Antimicrob Agents Chemother 54:3280-6. 2010
    ..h was obtained with a 10-mg/kg once-daily lamivudine (3TC) dose for children below 17 kg; the recommended dose of 8 mg/kg seems to be sufficient in children weighing more than 17 kg. These assumptions should be prospectively confirmed...
  3. ncbi Developmental pharmacokinetics of lamivudine in 580 pediatric patients ranging from neonates to adolescents
    Naïm Bouazza
    EA 3620, Universite Paris Descartes, Paris, France
    Antimicrob Agents Chemother 55:3498-504. 2011
    ....
  4. ncbi Population pharmacokinetics of tenofovir in HIV-1-infected pediatric patients
    Naïm Bouazza
    EA 3620, Universite Paris Descartes, Sorbonne Paris Cité France, Paris, France
    J Acquir Immune Defic Syndr 58:283-8. 2011
    ..The main goal was then to suggest for the first time the dose of tenofovir disoproxil fumarate (TDF) to give in children...
  5. ncbi Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients
    Naïm Bouazza
    EA 3620, Universite Paris Descartes, Sorbonne Paris Cité, France
    Orphanet J Rare Dis 6:86. 2011
    ..This study was aimed to describe the relationship between cysteamine plasma concentrations and white blood cell cystine levels, and to simulate an optimized administration scheme to improve the management of patients with cystinosis...
  6. ncbi Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women
    Sihem Benaboud
    Université Paris Descartes Sorbonne Paris Cité, EA3620, Paris, France
    Antimicrob Agents Chemother 56:857-62. 2012
    ....
  7. ncbi Pregnancy-related effects on lamivudine pharmacokinetics in a population study with 228 women
    Sihem Benaboud
    Universite Paris Descartes, Paris, France
    Antimicrob Agents Chemother 56:776-82. 2012
    ..9. Pregnant women had a 22% higher apparent clearance than nonpregnant and parturient women; however, this increase did not lead to subexposure and should not require a dosage adjustment...